Lilly experimental 'triple g' obesity drug leads to 24.2% weight loss in trial -NEJM

Eli Lilly's mid-stage trial of its next-generation "triple g" obesity drug candidate found that the highest dose of the weekly injection to led to weight loss of 24.2% after 48 weeks, the New England Journal of Medicine said on its website on Monday.

The drug, retatrutide, is part of a class known as incretins designed to mimic the action of the GLP-1 hormone, which helps regulate blood sugar, slow stomach emptying and decrease appetite. (Reporting By Deena Beasley, editing by Deepa Babington)

(This story has not been edited by Devdiscourse staff and is auto-generated from a syndicated feed.)